BIOLASE (NASDAQ:BIOL – Get Rating) will be announcing its earnings results after the market closes on Thursday, August 11th. BIOLASE has set its FY 2022 guidance at EPS and its Q2 2022 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.
BIOLASE (NASDAQ:BIOL – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The medical technology company reported ($0.81) earnings per share (EPS) for the quarter. BIOLASE had a negative return on equity of 62.40% and a negative net margin of 34.03%. The business had revenue of $10.17 million for the quarter.
BIOLASE Price Performance
BIOL stock opened at $4.74 on Thursday. The company has a quick ratio of 2.22, a current ratio of 3.34 and a debt-to-equity ratio of 0.66. BIOLASE has a 52-week low of $3.30 and a 52-week high of $23.49. The stock’s 50 day moving average is $4.48 and its two-hundred day moving average is $7.44. The company has a market capitalization of $29.27 million, a PE ratio of -2.30 and a beta of 1.48.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
An institutional investor recently raised its position in BIOLASE stock. State Street Corp boosted its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL – Get Rating) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 436,076 shares of the medical technology company’s stock after purchasing an additional 18,682 shares during the quarter. State Street Corp owned approximately 7.06% of BIOLASE worth $154,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.38% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.